Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Seattle Genetics, Inc. (SGEN)

« Back to company index

SGEN Chatter Timeline

Stock Ticker for SGEN

Most Active Tweeters for SGEN

UserTweets
@AmericanBanking 9
@ChartMill 4
@WeekHerald 4
@InsiderAlertsIA 3
@StockTexts 2

Recent Tweets for SGEN

smallinvestorhq @smallinvestorhq
RT @StockWatchHQ: Made Of Money_Spectrum Pharmaceuticals $SPPI And Seattle Genetics $SGEN Will Confirm Acquisition Agreement Terms, Announc…
June 17th 2019, 10:06pm
StockWatchHQ @StockWatchHQ
Made Of Money_Spectrum Pharmaceuticals $SPPI And Seattle Genetics $SGEN Will Confirm Acquisition Agreement Terms, A… https://t.co/tMQk8LKZ4x
June 17th 2019, 3:06pm
42Stocks @42Stocks
#SeattleGenetics up 5.4% = $596.7 million gain. $SGEN has made notable gains in 20 of the last 35 trading sessions,… https://t.co/QS92qiQCKU
June 17th 2019, 12:06pm
portefeuillefun @portefeuillefun
Sold 50 $SGEN at $71.27, now 300 #vssporte shares.
June 17th 2019, 10:06am
TheMarketsDaily @TheMarketsDaily
$191.20 Million in Sales Expected for Seattle Genetics, Inc. $SGEN This Quarter https://t.co/RpwvH0yglP
June 16th 2019, 7:06pm
dakotafinancial @dakotafinancial
Seattle Genetics $SGEN Cut to “Buy” at ValuEngine https://t.co/7pxnpyKNEA
June 15th 2019, 9:06am
IRAMarketReport @IRAMarketReport
Seattle Genetics, Inc. $SGEN Expected to Post Earnings of -$0.39 Per Share https://t.co/4nOuVFQSdH #markets
June 14th 2019, 7:06pm
chaffeybreeze @chaffeybreeze
Seattle Genetics, Inc. $SGEN Expected to Post Earnings of -$0.39 Per Share https://t.co/7ygG51w1Og #stocks
June 14th 2019, 7:06pm
AmericanBanking @AmericanBanking
Seattle Genetics, Inc. $SGEN Receives Consensus Rating of “Buy” from Analysts https://t.co/ruiivdolyg #stocks
June 14th 2019, 4:06am
dispatchtribune @dispatchtribune
Head-To-Head Comparison: Seattle Genetics $SGEN versus Surface Oncology $SURF https://t.co/r7EiPB5hu2
June 14th 2019, 4:06am
ZolmaxNews @ZolmaxNews
Seattle Genetics $SGEN Upgraded to “Buy” by BidaskClub https://t.co/GQSMFzyIew
June 14th 2019, 3:06am
AmericanBanking @AmericanBanking
Research Analysts’ Weekly Ratings Changes for Seattle Genetics $SGEN https://t.co/6a4sj9oybn #stocks
June 13th 2019, 2:06pm
registrarjourn @registrarjourn
Insider Selling: Seattle Genetics, Inc. $SGEN Insider Sells 20,148 Shares of Stock https://t.co/7zdOYJzooc
June 13th 2019, 1:06pm
EnterpriseLeade @EnterpriseLeade
Insider Selling: Seattle Genetics, Inc. $SGEN Insider Sells 20,148 Shares of Stock https://t.co/vqSWPPuoJN
June 13th 2019, 1:06pm
newswithvalue @newswithvalue
$MRK $SGEN: Key events next week – healthcare: https://t.co/OmVfWDpH7K
June 13th 2019, 7:06am
WeekHerald @WeekHerald
Seattle Genetics $SGEN Upgraded to “Buy” at BidaskClub https://t.co/PohjxWZKMQ
June 13th 2019, 4:06am
WatchlistN @WatchlistN
Seattle Genetics Target of Unusually High Options Trading $SGEN https://t.co/Pkdmbs1rRq
June 13th 2019, 1:06am
AmericanBanking @AmericanBanking
Seattle Genetics, Inc. $SGEN Insider Sells $1,391,219.40 in Stock https://t.co/8D6is7mUoY #stocks
June 12th 2019, 8:06pm
InsiderAlertsIA @InsiderAlertsIA
$SGEN: New Insider Filing on President and CEO CLAY B SIEGALL: https://t.co/9mxqV8oIDl
June 12th 2019, 6:06pm
StockTexts @StockTexts
$SGEN Seattle Genetics, Inc. SEC Filing: Form 4 https://t.co/xPmoA8Hgqf
June 12th 2019, 6:06pm
WKRBNews @WKRBNews
Seattle Genetics Sees Unusually Large Options Volume $SGEN https://t.co/q4QerNOOuu #markets
June 12th 2019, 8:06am
NewsToDesk @NewsToDesk
$SGEN: (Brentuximab Vedotin) Presentations at the Congress of the …: https://t.co/r9KrwgTTGg
June 12th 2019, 8:06am
AmericanBanking @AmericanBanking
Stock Traders Purchase Large Volume of Seattle Genetics Call Options $SGEN https://t.co/KfoHKkt7Ho #stocks
June 12th 2019, 8:06am
Allstocknews @Allstocknews
$SGEN Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of th From our Stock News Alerts App
June 12th 2019, 8:06am
ChartMill @ChartMill
$SGEN: The EPS growth is accelerating: in the next 2 years the growth will be better than in the last years.… https://t.co/ePp8T1ugdU
June 12th 2019, 5:06am
ThisLincolnian @ThisLincolnian
BidaskClub Upgrades Seattle Genetics $SGEN to Buy https://t.co/GPYgdq14sN
June 12th 2019, 2:06am
Gambiste1 @Gambiste1
RT @fda_tracker: $SGEN New PDUFA Date 2019-08-19 SEATTLE GENETICS, INC. Link:https://t.co/5mySfBrwWC Calendar:https://t.co/sCt1qKoMdr
June 11th 2019, 6:06pm
ChartMill @ChartMill
Based on estimates for the next 2 years, $SGEN will show a very strong growth in EPS: 35.63% on average per year.… https://t.co/Zks0iT5eBe
June 11th 2019, 5:06pm
fda_tracker @fda_tracker
$SGEN New PDUFA Date 2019-08-19 SEATTLE GENETICS, INC. Link:https://t.co/5mySfBrwWC Calendar:https://t.co/sCt1qKoMdr
June 11th 2019, 9:06am
Gambiste1 @Gambiste1
RT @1stOncology: #SeattleGenetics’ #AntibodyDrugConjugate Technology Utilized in #Genentech’s #Polivy, Now Approved by #FDA $SGEN https://t…
June 11th 2019, 8:06am
1stOncology @1stOncology
#SeattleGenetics’ #AntibodyDrugConjugate Technology Utilized in #Genentech’s #Polivy, Now Approved by #FDA $SGEN https://t.co/APvBJqh1Mn
June 11th 2019, 6:06am
ChartMill @ChartMill
Although the technical rating is bad, $SGEN does present a nice setup opportunity. https://t.co/eUFtBfBcPo https://t.co/IbWmR6Tvtv
June 10th 2019, 9:06pm
TheSkeptic21 @TheSkeptic21
$RHHBY/ Genentech/ $SGEN with first in class CD79b ADC for R/R-DLBCL
June 10th 2019, 1:06pm
ProVesting @ProVesting
$SGEN: Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in …: https://t.co/LyJNVNB0uV
June 10th 2019, 12:06pm
Allstocknews @Allstocknews
$SGEN Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FD From our Stock News Alerts App
June 10th 2019, 12:06pm
iluvstocks1 @iluvstocks1
$SGEN Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
June 10th 2019, 12:06pm
dispatchtribune @dispatchtribune
$191.20 Million in Sales Expected for Seattle Genetics, Inc. $SGEN This Quarter https://t.co/oUA6F1ukao
June 9th 2019, 1:06am
AmericanBanking @AmericanBanking
Zacks: Brokerages Expect Seattle Genetics, Inc. $SGEN Will Announce Quarterly Sales of $191.20 Million https://t.co/RF0nyRLd97 #stocks
June 9th 2019, 1:06am
WeekHerald @WeekHerald
Seattle Genetics $SGEN Given “Buy” Rating at William Blair https://t.co/Q9YiK89x4M
June 8th 2019, 7:06am
stocknewstimes @stocknewstimes
Zacks: Brokerages Expect Seattle Genetics, Inc. $SGEN to Post -$0.39 EPS https://t.co/aYQvXEEFJc
June 7th 2019, 8:06pm
SleekMoneycom @SleekMoneycom
Zacks: Brokerages Expect Seattle Genetics, Inc. $SGEN to Post -$0.39 EPS https://t.co/UZWHz8cAQT #investing
June 7th 2019, 8:06pm
AmericanBanking @AmericanBanking
Seattle Genetics, Inc. $SGEN Expected to Post Earnings of -$0.39 Per Share https://t.co/tNqPouDlcV #stocks
June 7th 2019, 8:06pm
InsiderAlertsIA @InsiderAlertsIA
$SGEN: New Insider Filing on 10%+ Owner BAKER BROS. ADVISORS LP: https://t.co/vfsT0FlFcu
June 7th 2019, 6:06pm
StockTexts @StockTexts
$SGEN Seattle Genetics, Inc. SEC Filing: Form 4 https://t.co/A4Yk4FVqBD
June 7th 2019, 6:06pm
StockSpotter @StockSpotter
$SGEN up 1.2% to 69.85 after our bullish setup alert Thu. Jun 6 after the close #swingtrading https://t.co/wtT4LjswgR
June 7th 2019, 11:06am
AmericanBanking @AmericanBanking
Seattle Genetics $SGEN & Surface Oncology $SURF Financial Review https://t.co/kMehzltoCb #stocks
June 7th 2019, 10:06am
WeekHerald @WeekHerald
Seattle Genetics $SGEN & Surface Oncology $SURF Financial Review https://t.co/gowTnszim5
June 7th 2019, 10:06am
WatchlistN @WatchlistN
William Blair Reiterates “Buy” Rating for Seattle Genetics $SGEN https://t.co/fAYizWYRvo
June 7th 2019, 5:06am
ChartMill @ChartMill
A Current Ratio of 3.27 indicates that $SGEN has no problem at all paying its short term obligations.… https://t.co/p5lextunRl
June 7th 2019, 3:06am
ThisLincolnian @ThisLincolnian
Seattle Genetics’ $SGEN “Buy” Rating Reiterated at William Blair https://t.co/jtxS8OhCFO
June 6th 2019, 8:06am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.